Editorial Material
Multidisciplinary Sciences
Maggie P. Lauria Sneideman, Victoria H. Meller
Summary: A protein that upregulates gene expression of the X chromosome has been discovered in male mosquitoes, which is crucial for equalizing gene expression between sexes in organisms with X and Y chromosomes.
Article
Oncology
Natsuki Teruya, Hiroaki Inoue, Rie Horii, Futoshi Akiyama, Takayuki Ueno, Shinji Ohno, Shunji Takahashi
Summary: The study investigated the predictive and prognostic value of intratumoral heterogeneity and conventional clinicopathological factors in ER+HER2+ breast cancer. The results showed that the composition of tumor cells was associated with prognosis, and the combination of posttreatment Ki67 and complete pathological response could more accurately predict prognosis.
Article
Multidisciplinary Sciences
Nindo B. Punturi, Sinem Seker, Vaishnavi Devarakonda, Aloran Mazumder, Rashi Kalra, Ching Hui Chen, Shunqiang Li, Tina Primeau, Matthew J. Ellis, Shyam M. Kavuri, Svasti Haricharan
Summary: Resistance to endocrine treatment in ER+ breast cancer patients is linked to activation of HER2 due to loss of mismatch repair, and inhibiting HER2 restores sensitivity to treatment. Loss of MutL and upregulation of HER2 are associated with sensitivity to HER inhibitors in ER+/HER2(-) patients.
NATURE COMMUNICATIONS
(2021)
Editorial Material
Multidisciplinary Sciences
Ronald Cutler, Jan Vijg
Summary: The study has shown that radiation-damaged paternal DNA causes embryos of the second generation of nematode worms, but not the first, to die. The proposed mechanisms explain why this effect is not observed in humans.
Article
Oncology
Lan Shu, Yiwei Tong, Zhuoxuan Li, Xiaosong Chen, Kunwei Shen
Summary: HER2 1+ cases of breast cancer are similar to HER2 0 cases in terms of clinicopathological features and mRNA expression, but different from HER2 2+/FISH- cases. There is poor concordance between IHC/FISH and qRT-PCR for HER2-negative tumors. The current definition of HER2-low expression with the lower boundary of HER2 IHC 1+ may be inaccurate.
Article
Oncology
Giuseppe Corona, Emanuela Di Gregorio, Alessia Vignoli, Elena Muraro, Agostino Steffan, Gianmaria Miolo
Summary: Dysregulation of lipid metabolism is a known characteristic of breast cancer, with a study using H-1-NMR analysis finding alterations in circulating lipoproteins in HER2-positive breast cancer patients, particularly elevated VLDL subfractions. Monitoring plasma lipoproteins profile changes during treatment interventions can help predict clinical outcomes. This underscores the importance of studying lipid metabolism in HER2-positive breast cancer for diagnostic and prognostic purposes.
Article
Biochemistry & Molecular Biology
Ana Peixoto, Luis Cirnes, Ana Luisa Carvalho, Maria Joao Andrade, Maria Jose Brito, Paula Borralho, Pedro M. Borralho, Ana Sofia Carneiro, Lisandra Castro, Lurdes Correia, Maria Rita Dionisio, Carlos Faria, Paulo Figueiredo, Ana Gomes, Joana Paixao, Manuela Pinheiro, Hugo Prazeres, Joana Ribeiro, Natalia Salgueiro, Fernando C. Schmitt, Fatima Silva, Ana Rita Silvestre, Ana Carla Sousa, Joana Almeida-Tavares, Manuel R. Teixeira, Saudade Andre, Jose Carlos Machado
Summary: The U-PIK project aimed to validate and implement the PIK3CA mutation testing in multiple Portuguese centers, and the testing results showed high concordance rates between the method used by each tester center and NGS, demonstrating the importance of this test in clinical practice for ER+/HER2-BC patients eligible for PI3K alpha inhibitor treatment.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2023)
Article
Pathology
Paul Weisman, Monica Ospina-Romero, Qiqi Yu, Kari Wisinski, Jin Xu
Summary: This study found that in HER2+ breast cancer patients, tumors with low ER expression have a similar pathological response to chemotherapy as ER-negative tumors, while tumors with high ER expression have a higher risk of residual cancer.
PATHOLOGY RESEARCH AND PRACTICE
(2022)
Article
Oncology
Elisa Agostinetto, Mattia Rediti, Danai Fimereli, Veronique Debien, Martine Piccart, Philippe Aftimos, Christos Sotiriou, Evandro de Azambuja
Summary: The study characterized PAM50 intrinsic subtypes within HER2-low breast cancer and investigated the prognostic impact of HER2-low status on survival outcomes. The distribution of HER2-enriched tumors was higher in the HER2-low/HR- group compared to the HER2-low/HR+ group. However, there were no significant differences in survival outcomes between HER2-low subtypes and each non-HER2-low subtype when paired by HR status.
Article
Oncology
Sibylle Loibl, Chiun-Sheng Huang, Max S. Mano, Eleftherios P. Mamounas, Charles E. Geyer, Michael Untch, Jean-Christophe Thery, Ingo Schwaner, Steven Limentani, Niklas Loman, Kristina Lubbe, Jenny C. Chang, Thomas Hatschek, David Tesarowski, Chunyan Song, Sanne Lysbet de Haas, Thomas Boulet, Chiara Lambertini, Norman Wolmark
Summary: In HER2-negative breast cancer patients, T-DM1 treatment may be more effective than trastuzumab.
Review
Oncology
Nandini Dey, Jennifer Aske, Pradip De
Summary: A high pathological complete response in neoadjuvant therapy is associated with better overall response but is challenging to achieve in ER-positive breast cancers. Strategies to induce apoptosis based on genomic alterations are proposed, as neoadjuvant therapy offers a unique opportunity for personalized insight into tumor biology and drug response.
Article
Oncology
Qiang Liu, Yihang Qi, Xiangyi Kong, Xiangyu Wang, Wenxiang Zhang, Jie Zhai, Yazhe Yang, Yi Fang, Jing Wang
Summary: Molecular chaperones, such as the CCT/TRiC complex, play important roles in cellular processes and cancer development. The study found that CCT2, a subunit of the complex, is significantly upregulated in various tumors and independently predicts worse prognosis in breast cancer patients, especially in the luminal A subtype. This comprehensive analysis expands our understanding of CCT2 and its potential as a target for anti-cancer treatments.
FRONTIERS IN ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Sandra Orru, Emanuele Pascariello, Giovanni Sotgiu, Daniela Piras, Laura Saderi, Maria Rosaria Muroni, Ciriaco Carru, Caterina Arru, Cristina Mocci, Giampietro Pinna, Raffaele Barbara, Paolo Cossu-Rocca, Maria Rosaria De Miglio
Summary: In HER2+ breast cancer, AR expression is prevalent, with minimal differences in expression between different subtypes of tumors, but significant differences in other characteristics. The expression of AR significantly impacts prognosis in HER2+ breast cancer.
Article
Oncology
Maryam Althobiti, Khloud A. El-sharawy, Chitra Joseph, Mohammed Aleskandarany, Michael S. Toss, Andrew R. Green, Emad A. Rakha
Summary: SLC39A6 may have prognostic value for a better outcome in ER + luminal breast cancer, with high expression being associated with longer BC-specific survival even in patients who did not receive endocrine therapy. Further functional studies on the role of SLC39A6 in ER + luminal breast cancer are warranted.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Article
Oncology
Katrin Almstedt, Anne-Sophie Heimes, Franziska Kappenberg, Marco J. Battista, Hans-Anton Lehr, Slavomir Krajnak, Antje Lebrecht, Mathias Gehrmann, Kathrin Stewen, Walburgis Brenner, Wolfgang Weikel, Joerg Rahnenfuehrer, Jan G. Hengstler, Annette Hasenburg, Marcus Schmidt
Summary: This study found that in breast cancer patients without lymph node metastasis, patients with HER2-low tumors had better prognosis compared to those with HER2-zero tumors. The HER2 status has independent prognostic significance for both disease-free survival and overall survival.
EUROPEAN JOURNAL OF CANCER
(2022)